NCT02949596

Brief Summary

Treatment of anal cancer has been always linked to quality of life. Recently, with development on radiotherapy technique, toxicities have been lowered with the maintenance of adequate rates of disease control. This trial intends to follow patients prospectively with questionnaires to evaluate sexual quality of life among patients who are who men who have sex with other men and have been subject to concurrent chemoradiotherapy with IMRT technique.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
19

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2015

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2015

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

October 25, 2016

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 31, 2016

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2020

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2021

Completed
Last Updated

February 9, 2021

Status Verified

February 1, 2021

Enrollment Period

5 years

First QC Date

October 25, 2016

Last Update Submit

February 8, 2021

Conditions

Keywords

quality of sexual lifeintensity-modulated radiotherapyconcurrent chemoradiotherapy

Outcome Measures

Primary Outcomes (3)

  • Evaluate quality of life validated questionnaire (EORTC QLQ-30) among patients treated for anal cancer with concurrent chemoradiotherapy who are men who have sex with other men

    2015-2020

  • Evaluate quality of life validated questionnaire (SF-36) among patients treated for anal cancer with concurrent chemoradiotherapy who are men who have sex with other men

    2015-2020

  • Evaluate quality of sexual life validated questionnaire (IIEF) among patients treated for anal cancer with concurrent chemoradiotherapy who are men who have sex with other men

    2015-2020

Secondary Outcomes (8)

  • Evaluate quality of sexual life with other questionnaires (CSFQ-14) that are not validated in Portuguese language in the same population

    2015-2020

  • Evaluate quality of sexual life with other questionnaires (ISL) in the same population

    2015-2020

  • Evaluate quality of sexual life with other questionnaires (MSHQ-short version) in the same population

    2015-2020

  • Evaluate quality of sexual life with other questionnaires (SEAR) in the same population

    2015-2020

  • Evaluate quality of sexual life with other questionnaires (SEX-Q) in the same population

    2015-2020

  • +3 more secondary outcomes

Interventions

Eligibility Criteria

Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with anal cancer who are men who have sex with other men and are able to answer to questionnaires

You may qualify if:

  • Anal cancer proven biopsy
  • men who have sex with other men
  • curative intent of treatment
  • IMRT required
  • concurrent chemotherapy required

You may not qualify if:

  • Patients who have undergone surgery for anal cancer
  • patients who can't read, write or are unable to answer to questionnaire

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ICESP

São Paulo, 01.246-903, Brazil

Location

MeSH Terms

Conditions

Anus Neoplasms

Interventions

Quality of Life

Condition Hierarchy (Ancestors)

Rectal NeoplasmsColorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesIntestinal DiseasesAnus DiseasesRectal Diseases

Intervention Hierarchy (Ancestors)

Health StatusDemographyEpidemiologic MeasurementsPublic HealthEnvironment and Public Health

Study Officials

  • Geovanne Mauro, MD

    physician

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

October 25, 2016

First Posted

October 31, 2016

Study Start

October 1, 2015

Primary Completion

October 1, 2020

Study Completion

February 1, 2021

Last Updated

February 9, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will not share

Locations